- Home
- NBIX vs GTLB Comparison
NBIX vs GTLB Comparison
Compare NBIX & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- GTLB
- Stock Information
- Founded
- NBIX 1992
- GTLB 2011
- Country
- NBIX United States
- GTLB United States
- Employees
- NBIX N/A
- GTLB N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- GTLB EDP Services
- Sector
- NBIX Health Care
- GTLB Technology
- Exchange
- NBIX Nasdaq
- GTLB Nasdaq
- Market Cap
- NBIX 11.0B
- GTLB 11.0B
- IPO Year
- NBIX 1996
- GTLB 2021
- Fundamental
- Price
- NBIX $87.58
- GTLB $40.52
- Analyst Decision
- NBIX Buy
- GTLB Strong Buy
- Analyst Count
- NBIX 21
- GTLB 23
- Target Price
- NBIX $164.80
- GTLB $74.22
- AVG Volume (30 Days)
- NBIX 1.3M
- GTLB 2.3M
- Earning Date
- NBIX 04-30-2025
- GTLB 06-02-2025
- Dividend Yield
- NBIX N/A
- GTLB N/A
- EPS Growth
- NBIX 33.20
- GTLB N/A
- EPS
- NBIX 3.29
- GTLB N/A
- Revenue
- NBIX $2,355,300,000.00
- GTLB $759,249,000.00
- Revenue This Year
- NBIX $15.48
- GTLB $26.55
- Revenue Next Year
- NBIX $16.18
- GTLB $22.39
- P/E Ratio
- NBIX $26.38
- GTLB N/A
- Revenue Growth
- NBIX 24.81
- GTLB 30.93
- 52 Week Low
- NBIX $86.58
- GTLB $37.90
- 52 Week High
- NBIX $157.98
- GTLB $74.18
- Technical
- Relative Strength Index (RSI)
- NBIX 20.83
- GTLB 28.79
- Support Level
- NBIX $113.05
- GTLB $37.90
- Resistance Level
- NBIX $112.74
- GTLB $48.88
- Average True Range (ATR)
- NBIX 3.20
- GTLB 2.60
- MACD
- NBIX -1.46
- GTLB -0.55
- Stochastic Oscillator
- NBIX 4.59
- GTLB 16.76
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About GTLB GitLab Inc.
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.